|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hossain MS, Karuniawati H, Jairoun AA,
Urbi Z, Ooi J, John A, Lim YC, Kibria KMK, Mohiuddin AKM, Ming LC,
et al: Colorectal cancer: A review of carcinogenesis, global
epidemiology, current challenges, risk factors, preventive and
treatment strategies. Cancers (Basel). 14:17322022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Biller LH and Schrag D: Diagnosis and
treatment of metastatic colorectal cancer: A review. JAMA.
325:669–685. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cervantes A, Adam R, Roselló S, Arnold D,
Normanno N, Taïeb J, Seligmann J, De Baere T, Osterlund P, Yoshino
T, et al: Metastatic colorectal cancer: ESMO clinical practice
guideline for diagnosis, treatment and follow-up. Ann Oncol.
34:10–32. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zeng T, Fang X, Lu J, Zhong Y, Lin X, Lin
Z, Wang N, Jiang J and Lin S: Efficacy and safety of immune
checkpoint inhibitors in colorectal cancer: A systematic review and
meta-analysis. Int J Colorectal Dis. 37:251–258. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ganesh K, Stadler ZK, Cercek A, Mendelsohn
RB, Shia J, Segal NH and Diaz LA Jr: Immunotherapy in colorectal
cancer: Rationale, challenges and potential. Nat Rev Gastroenterol
Hepatol. 16:361–375. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xie YH, Chen YX and Fang JY: Comprehensive
review of targeted therapy for colorectal cancer. Signal Transduct
Target Ther. 5:222020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hutton B, Salanti G, Caldwell DM, Chaimani
A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen
JP, et al: The PRISMA extension statement for reporting of
systematic reviews incorporating network meta-analyses of health
care interventions: Checklist and explanations. Ann Intern Med.
162:777–784. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chaimani A, Caldwell DM, Li T, Higgins JPT
and Salanti G: Chapter 11: Undertaking network meta-analyses.
Cochrane Handbook for Systematic Reviews of Interventions version
6.3. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ
and Welch VA: Cochrane; Alberta: 2024
|
|
10
|
Deeks JJ, Higgins JPT and Altman DG:
Chapter 10: Analysing data and undertaking meta-analyses. Cochrane
Handbook for Systematic Reviews of Interventions version 6.4.
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ and
Welch VA: Cochrane; Alberta: 2023
|
|
11
|
Higgins JPT, Eldridge S and Li T: Chapter
23: Including variants on randomized trials. Cochrane Handbook for
Systematic Reviews of Interventions version 6.5. Higgins JPT,
Thomas J, Chandler J, Cumpston M, Li T, Page MJ and Welch VA:
Cochrane; Alberta: 2024
|
|
12
|
Page MJ, Higgins JPT and Sterne JAC:
Chapter 13: Assessing risk of bias due to missing results in a
synthesis. Cochrane Handbook for Systematic Reviews of
Interventions version 6.5. Higgins JPT, Thomas J, Chandler J,
Cumpston M, Li T, Page MJ and Welch VA: Cochrane; Alberta: 2024
|
|
13
|
Sterne JAC, Savović J, Page MJ, Elbers RG,
Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge
SM, et al: RoB 2: A revised tool for assessing risk of bias in
randomised trials. BMJ. 366:l48982019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
U.S. Food and Drug Administration, .
Guidance for industry: Toxicity grading scale for healthy adult and
adolescent volunteers enrolled in preventive vaccine clinical
trials. 2007.
|
|
15
|
Borenstein M, Hedges LV, Higgins JPT and
Rothstein HR: Fixed-effect versus random-effects models.
Introduction to Meta-Analysis. John Wiley & Sons Ltd.; Oxford:
pp. 77–86. 2009, View Article : Google Scholar
|
|
16
|
Owen RK, Bradbury N, Xin Y, Cooper N and
Sutton A: MetaInsight: An interactive web-based tool for analyzing,
interrogating, and visualizing network meta-analyses using R-shiny
and netmeta. Res Synth Methods. 10:569–581. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eng C, Kim TW, Bendell J, Argilés G,
Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal
NH, et al: Atezolizumab with or without cobimetinib versus
regorafenib in previously treated metastatic colorectal cancer
(IMblaze370): A multicentre, open-label, phase 3, randomised,
controlled trial. Lancet Oncol. 20:849–861. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
André T, Shiu KK, Kim TW, Jensen BV,
Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs
P, et al: Pembrolizumab in microsatellite-instability-high advanced
colorectal cancer. N Engl J Med. 383:2207–2218. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen EX, Jonker DJ, Loree JM, Kennecke HF,
Berry SR, Couture F, Ahmad CE, Goffin JR, Kavan P, Harb M, et al:
Effect of combined immune checkpoint inhibition vs best supportive
care alone in patients with advanced colorectal cancer: The
Canadian cancer trials group CO.26 study. JAMA Oncol. 6:831–838.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lonardi S, Prete AA, Morano F, Messina M,
Formica V, Corsi DC, Orciuolo C, Frassineti GL, Zampino MG,
Casagrande M, et al: Randomized phase II trial of avelumab alone or
in combination with cetuximab for patients with previously treated,
locally advanced, or metastatic squamous cell anal carcinoma: The
CARACAS study. J Immunother Cancer. 9:e0029962021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Antoniotti C, Rossini D, Pietrantonio F,
Catteau A, Salvatore L, Lonardi S, Boquet I, Tamberi S, Marmorino
F, Moretto R, et al: Upfront FOLFOXIRI plus bevacizumab with or
without atezolizumab in the treatment of patients with metastatic
colorectal cancer (AtezoTRIBE): A multicentre, open-label,
randomised, controlled, phase 2 trial. Lancet Oncol. 23:876–887.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Meltzer S, Negård A, Bakke KM, Hamre HM,
Kersten C, Hofsli E, Guren MG, Sorbye H, Flatmark K and Ree AH:
Early radiologic signal of responsiveness to immune checkpoint
blockade in microsatellite-stable/mismatch repair-proficient
metastatic colorectal cancer. Br J Cancer. 127:2227–2233. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Redman JM, Tsai YT, Weinberg BA, Donahue
RN, Gandhy S, Gatti-Mays ME, Abdul Sater H, Bilusic M, Cordes LM,
Steinberg SM, et al: A randomized phase II trial of mFOLFOX6 +
bevacizumab alone or with AdCEA vaccine + avelumab immunotherapy
for untreated metastatic colorectal cancer. Oncologist. 27:198–209.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tabernero J, Grothey A, Arnold D, de
Gramont A, Ducreux M, O'Dwyer P, Tahiri A, Gilberg F, Irahara N,
Schmoll HJ and Van Cutsem E: MODUL cohort 2: an adaptable,
randomized, signal-seeking trial of fluoropyrimidine plus
bevacizumab with or without atezolizumab maintenance therapy for
BRAFwt metastatic colorectal cancer. ESMO Open.
7:1005592022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ducreux M, Tabernero J, Grothey A, Arnold
D, O'Dwyer PJ, Gilberg F, Abbas A, Thakur MD, Prizant H, Irahara N,
et al: Clinical and exploratory biomarker findings from the MODUL
trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy
for metastatic colorectal cancer. Eur J Cancer. 184:137–150. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Monge C, Xie CQ, Myojin Y, Coffman K,
Hrones DM, Wang S, Hernandez JM, Wood BJ, Levy EB, Juburi I, et al:
Phase I/II study of PexaVec in combination with immune checkpoint
inhibition in refractory metastatic colorectal cancer. J Immunother
Cancer. 11:e0056402023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Taïeb J, Bouche O, André T, Le Malicot K,
Laurent-Puig P, Bez J, Toullec C, Borg C, Randrian V, Evesque L, et
al: Avelumab vs standard second-line chemotherapy in patients with
metastatic colorectal cancer and microsatellite instability: A
randomized clinical trial. JAMA Oncol. 9:1356–1363. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mettu NB, Ou FS, Zemla TJ, Halfdanarson
TR, Lenz HJ, Breakstone RA, Boland PM, Crysler OV, Wu C, Nixon AB,
et al: Assessment of capecitabine and bevacizumab with or without
atezolizumab for the treatment of refractory metastatic colorectal
cancer: A randomized clinical Trial. JAMA Netw Open.
5:e21490402022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Han Y, Liu D and Li L: PD-1/PD-L1 pathway:
Current researches in cancer. Am J Cancer Res. 10:727–742.
2020.PubMed/NCBI
|
|
30
|
Shan T, Chen S, Wu T, Yang Y, Li S and
Chen X: PD-L1 expression in colon cancer and its relationship with
clinical prognosis. Int J Clin Exp Pathol. 12:1764–1769.
2019.PubMed/NCBI
|
|
31
|
Chen L and Han X: Anti-PD-1/PD-L1 therapy
of human cancer: Past, present, and future. J Clin Invest.
125:3384–3391. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sobhani N, Tardiel-Cyril DR, Davtyan A,
Generali D, Roudi R and Li Y: CTLA-4 in regulatory T cells for
cancer immunotherapy. Cancers (Basel). 13:14402021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Buchbinder EI and Desai A: CTLA-4 and PD-1
pathways: Similarities, differences, and implications of their
inhibition. Am J Clin Oncol. 39:98–106. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu AA, Bever KM, Ho WJ, Fertig EJ, Niu N,
Zheng L, Parkinson RM, Durham JN, Onners B, Ferguson AK, et al: A
phase II study of allogeneic GM-CSF-transfected pancreatic tumor
vaccine (GVAX) with ipilimumab as maintenance treatment for
metastatic pancreatic cancer. Clin Cancer Res. 26:5129–5139. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Manz SM, Losa M, Fritsch R and Scharl M:
Efficacy and side effects of immune checkpoint inhibitors in the
treatment of colorectal cancer. Therap Adv Gastroenterol.
14:175628482110020182021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schneider BJ, Naidoo J, Santomasso BD,
Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino
JM, Chau I, et al: Management of immune-related adverse events in
patients treated with immune checkpoint inhibitor therapy: ASCO
guideline update. J Clin Oncol. 39:4073–4126. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Carbone DP, Reck M, Paz-Ares L, Creelan B,
Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F,
et al: First-line nivolumab in stage IV or recurrent non-small-cell
lung cancer. N Engl J Med. 376:2415–2426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jove M, Vilariño N and Nadal E: Impact of
baseline steroids on efficacy of programmed cell death-1 (PD-1) and
programmed death-ligand 1 (PD-L1) blockade in patients with
advanced non-small cell lung cancer. Transl Lung Cancer Res. 8
(Suppl 4):S364–S368. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Van Buren I, Madison C, Kohn A, Berry E,
Kulkarni RP and Thompson RF: Survival among veterans receiving
steroids for immune-related adverse events after immune checkpoint
inhibitor therapy. JAMA Netw Open. 6:e23406952023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Byron Y, Yegorova-Lee S and Tio M: Do
corticosteroids affect immunotherapy efficacy in malignancy? A
systematic review. J Clin Oncol. 41:e146922023. View Article : Google Scholar
|
|
42
|
Tokunaga A, Sugiyama D, Maeda Y, Warner
AB, Panageas KS, Ito S, Togashi Y, Sakai C, Wolchok JD and
Nishikawa H: Selective inhibition of low-affinity memory
CD8+ T cells by corticosteroids. J Exp Med.
216:2701–2713. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Maslov DV, Tawagi K, Kc M, Simenson V,
Yuan H, Parent C, Bamnolker A, Goel R, Blake Z, Matrana MR and
Johnson DH: Timing of steroid initiation and response rates to
immune checkpoint inhibitors in metastatic cancer. J Immunother
Cancer. 9:e0022612021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu P, Ye M, Wu Y, Wu L, Lan K and Wu Z:
Hyperthermia combined with immune checkpoint inhibitor therapy:
Synergistic sensitization and clinical outcomes. Cancer Med.
12:3201–3221. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yang X, Gao M, Xu R, Tao Y, Luo W, Wang B,
Zhong W, He L and He Y: Hyperthermia combined with immune
checkpoint inhibitor therapy in the treatment of primary and
metastatic tumors. Front Immunol. 13:9694472022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Duffy AG, Ulahannan SV, Makorova-Rusher O,
Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T,
ElGindi M, et al: Tremelimumab in combination with ablation in
patients with advanced hepatocellular carcinoma. J Hepatol.
66:545–551. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lyu N, Kong Y, Li X, Mu L, Deng H, Chen H,
He M, Lai J, Li J, Tang H, et al: Ablation reboots the response in
advanced hepatocellular carcinoma with stable or atypical response
during PD-1 therapy: A proof-of-concept study. Front Oncol.
10:5802412020. View Article : Google Scholar : PubMed/NCBI
|
